Quantcast

Latest Cipher Pharmaceuticals Inc. Stories

2011-06-29 07:30:00

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, June 29, 2011 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND) ("Cipher" or "the Company") today announced that it has entered into a definitive distribution and supply agreement with Vertical Pharmaceuticals, Inc. ("Vertical"), a U.S.-based specialty pharmaceutical company, under which Cipher has granted Vertical the exclusive right to market, sell and distribute CIP-TRAMADOL ER in the United States. CIP-TRAMADOL ER is a...

2011-06-07 07:00:00

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, June 7, 2011 /PRNewswire/ - Cipher Pharmaceuticals Inc. (TSX: DND) today provided top-line safety and efficacy results from the Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin for the treatment of severe, nodular acne.  The 925-patient study was a randomized, double-blinded trial comparing the safety profile of CIP-ISOTRETINOIN to a commercially available isotretinoin...

2010-12-07 10:35:00

HAMILTON, N.J., Dec. 7, 2010 /PRNewswire/ -- MedAvante, Inc., the leader in centralized expert evaluation of treatments for central nervous system disorders, announced that Cipher Pharmaceuticals is using MedAvante Centralized Ratings in their pivotal Phase 3 dermatology study. Cipher recently announced the completion of the patient enrollment phase of their clinical study, in which every patient is interviewed by a qualified MedAvante mental health expert at every visit of the study....

2010-10-29 07:30:00

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, Oct. 29 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced that it has completed patient enrolment in its Phase III safety study of CIP-ISOTRETINOIN, the Company's novel, patented formulation of isotretinoin, which is used in the treatment of severe, nodular acne. The Phase III safety study is being conducted under a Special Protocol Assessment that was granted by the U.S. Food and Drug...

2010-05-10 06:00:00

Toronto Stock Exchange Symbol: DND MISSISSAUGA, ON, May 10 /PRNewswire-FirstCall/ - Cipher Pharmaceuticals Inc. (TSX: DND) today announced the U.S. Food and Drug Administration ("FDA") has approved CIP-TRAMADOL ER, the Company's extended-release tramadol product, for the treatment of moderate to moderately severe chronic pain in adults. "This represents our second FDA approval - a major achievement for the Company that reflects a significant amount of effort and dedication from our team, led...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related